An Insider’s View: Report on the Finnish Life Sciences Industry
University of Helsinki
Anne-Sisko Patana, Tamara Carleton, Kirsi Polvinen, Laura Kanto, Hanna Nordlund, Jussi Pihlajamaa, Pekka Berg
This study provides several benefits to practitioners and researchers in the biotech field, as well as others looking for greater insight into Finnish biotech innovation. These benefits are explained below.
The Perceived Value-added of Venture Capital Investors: Evidence from Finnish biotechnology industry
ETLA publication no 1030, 2006
This study focuses on the non-financial value-added of venture capital investors (VCs) as perceived by the CEOs of Finnish biotechnology companies. It pays attention to differences in the value-added between informal venture capitalists, private sector venture capitalists and public sector venture capital organizations. In addition, this study pays attention to value-adding mechanisms which venture capitalists use in developing their portfolio companies and factors which influence the perceived value-added.
Coaching small biotech companies into success: The value-adding function of VC
ETLA publication no 1032, 2006
The paper reports an empirical study on the non-financial value-added provided by Venture Capital investors to their investee firms. This study will use a four-class grouping of the various non-financial value-adding capabilities provided by VC firms, namely, scouting, monitoring, signalling and value-adding services. The study examines biotechnology industry in Finland.